Akero Therapeutics, Inc.
(NASDAQ : AKRO)

( )
AKRO After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
LLYEli Lilly & Co. -0.18%370.421.1%$1216.50m
JNJJohnson & Johnson 0.43%178.760.7%$1165.03m
MRKMerck & Co., Inc. -0.26%109.830.7%$1038.47m
PFEPfizer Inc. 2.02%51.140.9%$1008.93m
ABBVAbbVie, Inc. 0.25%161.581.9%$870.39m
BMYBristol-Myers Squibb Co. 0.74%80.871.1%$766.18m
AZNAstraZeneca Plc 0.54%68.341.0%$362.77m
HZNPHorizon Therapeutics Plc 0.59%100.885.4%$307.91m
IDXXIDEXX Laboratories, Inc. 3.12%439.173.9%$238.83m
CTLTCatalent, Inc. 4.21%52.241.9%$232.12m
GSKGSK Plc 1.29%35.040.3%$196.56m
NVSNovartis AG 0.28%89.810.2%$189.49m
NVONovo Nordisk A/S 1.22%126.130.1%$174.86m
ALNYAlnylam Pharmaceuticals, Inc. -0.15%220.258.0%$161.88m
RGENRepligen Corp. 5.22%188.176.7%$140.92m

Company Profile

Akero Therapeutics, Inc. operates as a cardio-metabolic nonalcoholic steatohepatitis company, which engages in developing pioneering medicines designed to restore metabolic balance and improve overall health. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.